NO20031671L - Dioksolananaloger for forbedret intercellulaer avlevering - Google Patents

Dioksolananaloger for forbedret intercellulaer avlevering

Info

Publication number
NO20031671L
NO20031671L NO20031671A NO20031671A NO20031671L NO 20031671 L NO20031671 L NO 20031671L NO 20031671 A NO20031671 A NO 20031671A NO 20031671 A NO20031671 A NO 20031671A NO 20031671 L NO20031671 L NO 20031671L
Authority
NO
Norway
Prior art keywords
alkyl
alkenyl
aryl
case
aromatic ring
Prior art date
Application number
NO20031671A
Other languages
English (en)
Other versions
NO20031671D0 (no
Inventor
Rabindra N Rej
Giorgio Attardo
Jean-Francois Lavallee
Boulos Zacharie
Louis Vaillancourt
Real Denis
Sophie Levesque
Charles Blais
Monica Bubenik
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of NO20031671D0 publication Critical patent/NO20031671D0/no
Publication of NO20031671L publication Critical patent/NO20031671L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser som har den følgende formel (I). hvor Ri er f.eks. H, C_-alkyl, C--alkenyl, C--aryl, C.-heteroaromatisk ring eller C_-ikke-aromatisk ring; Rog Rer f.eks. i hvert tilfelle uavhengig av hverandre H, C--alkyl, C--alkenyl, C--aryl, C_-heteroaromatisk ring eller C.-ikke-aromatisk ring; eller et aminosyreradikal eller en. dipeptid- eller tripeptidkjede eller etterligning derav, hvor aminosyreradikalene er valgt fra gruppen som omfatter Glu, Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Ser, Thr, Cys, Met, Asn og Gin, og som i hvert tilfelle eventuelt er avsluttet med -R.; Rer i hvert tilfelle H, C.-alkyl, C.-alkenyl, C.-alkyl-C.-aryl, Co-o-alkyl-C_-heteroaromatisk ring, C.-ikkearomatisk ring som eventuelt inneholder 1-3. heteroatomer valgt fra gruppen som omfatter 0, N og S; og R7 er i hvert tilfelle C_-alkyl, C--alkenyl, Ce-io-aryl, C.-heteroaromatisk ring, C.-ikke-aromatisk ring som eventuelt inneholder 1-3 heteroatomer valgt fra gruppen som omfatter 0, N og S, -C(0)R, -C(0)OR; og X og Y er uavhengig av hverandre Br, Cl, I, F, OH, 0Reller NRR, og minst én av X og Y er NRR; eller et farmasøytisk akseptabelt salt derav, kan anvendes ved behandling av en pasient som har kreft.
NO20031671A 2000-10-13 2003-04-11 Dioksolananaloger for forbedret intercellulaer avlevering NO20031671L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23988500P 2000-10-13 2000-10-13
US28842401P 2001-05-04 2001-05-04
PCT/CA2001/001464 WO2002030922A2 (en) 2000-10-13 2001-10-15 Dioxolane analogs for improved inter-cellular delivery

Publications (2)

Publication Number Publication Date
NO20031671D0 NO20031671D0 (no) 2003-04-11
NO20031671L true NO20031671L (no) 2003-06-13

Family

ID=26932965

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031671A NO20031671L (no) 2000-10-13 2003-04-11 Dioksolananaloger for forbedret intercellulaer avlevering

Country Status (13)

Country Link
US (2) US20030013660A1 (no)
EP (1) EP1324997A2 (no)
JP (1) JP2004510832A (no)
KR (1) KR20030096226A (no)
CN (1) CN100376570C (no)
AU (2) AU2002212015B2 (no)
CA (1) CA2425359A1 (no)
HU (1) HUP0301363A2 (no)
MX (1) MXPA03003278A (no)
NO (1) NO20031671L (no)
NZ (1) NZ537432A (no)
PL (1) PL361310A1 (no)
WO (1) WO2002030922A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
AU2002365234B2 (en) * 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
GB0306907D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
CA2554782C (en) * 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
DK2462134T3 (da) 2009-08-07 2014-08-11 Dow Agrosciences Llc N1-sulfonyl-5-fluorpyrimidinonderivater
KR101444693B1 (ko) * 2011-06-06 2014-09-26 아버 테라퓨틱스 엘엘씨 암 화학요법제의 산에 불안정한 친유성 전구약물
JP6324994B2 (ja) 2012-12-28 2018-05-16 アダマ・マクテシム・リミテッド N−(置換)−5−フルオロ−4−イミノ−3−メチル−2−オキソ−3,4−ジヒドロピリミジン−1(2h)−カルボキシレート誘導体
KR20150100869A (ko) 2012-12-28 2015-09-02 다우 아그로사이언시즈 엘엘씨 N-(치환된)-5-플루오로-4-이미노-3-메틸-2-옥소-3,4-디히드로피리미딘-1(2h)-카르복스아미드 유도체
CN105007737A (zh) 2012-12-31 2015-10-28 美国陶氏益农公司 作为杀真菌剂的3-烷基-5-氟-4-取代的-亚氨基-3,4-二氢嘧啶-2(1h)-酮衍生物
JP6585057B2 (ja) 2013-12-31 2019-10-02 アダマ・マクテシム・リミテッド 5−フルオロ−4−イミノ−3−(アルキル/置換アルキル)−1−(アリールスルホニル)−3,4−ジヒドロピリミジン−2(1h)−オンおよびそれらの調製方法
CN114794123B (zh) 2013-12-31 2024-11-12 阿达玛马克西姆股份有限公司 用防治谷类中真菌的协同杀真菌混合物
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
WO2016077832A2 (en) * 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
TWI687431B (zh) 2015-06-22 2020-03-11 瑞典商米迪維艾克提伯拉公司 治療癌症之前藥
US10167253B2 (en) * 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
CA3014769C (en) * 2016-03-02 2024-01-09 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CA3059073A1 (en) 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
WO2000057861A2 (en) * 1999-03-29 2000-10-05 Shire Biochem Inc. Use of cytidine derivatives for the treatment of leukaemia
ATE360016T1 (de) * 2000-02-11 2007-05-15 Shire Biochem Inc Ein stereoselektives verfahren zur herstellung von nukleosidanalogen

Also Published As

Publication number Publication date
CN100376570C (zh) 2008-03-26
US20050256034A1 (en) 2005-11-17
PL361310A1 (en) 2004-10-04
CA2425359A1 (en) 2002-04-18
WO2002030922A3 (en) 2002-09-26
AU2002212015B2 (en) 2007-01-25
CN1471526A (zh) 2004-01-28
US20030013660A1 (en) 2003-01-16
KR20030096226A (ko) 2003-12-24
JP2004510832A (ja) 2004-04-08
NO20031671D0 (no) 2003-04-11
MXPA03003278A (es) 2005-07-01
WO2002030922A2 (en) 2002-04-18
AU1201502A (en) 2002-04-22
EP1324997A2 (en) 2003-07-09
HUP0301363A2 (hu) 2005-12-28
NZ537432A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
NO20031671L (no) Dioksolananaloger for forbedret intercellulaer avlevering
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
NO911854L (no) Fremgangsmaate for fremstilling av peptid-derivater.
HUP0103511A2 (hu) Oxazolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
MY135057A (en) Dolastatin 15 derivatives
NO980195L (no) Cyklosporinderivater med anti-HIV-effekt
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
KR910006324A (ko) 펩티다아제 및 아이소머라제 억제제
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69533174D1 (de) Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
RU2003101319A (ru) Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
MXPA05013587A (es) Agentes terapeuticos utiles para el tratamiento del dolor.
NO157935C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider.
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
AU6999796A (en) Heterocyclic compounds as bradykinin antagonists
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
DE602004006379D1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
HUT55034A (en) Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient
NO941151L (no) Lineære adhesjonsinhibitorer
GB984810A (en) Polypeptides
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények